Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
43.31
-0.34 (-0.78%)
Nov 21, 2024, 2:03 PM EST - Market open
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $2.34M in the quarter ending September 30, 2024, a decrease of -17.10%. This brings the company's revenue in the last twelve months to $10.12M, down -0.19% year-over-year. In the year 2023, Avidity Biosciences had annual revenue of $9.56M with 3.64% growth.
Revenue (ttm)
$10.12M
Revenue Growth
-0.19%
P/S Ratio
n/a
Revenue / Employee
$39,988
Employees
253
Market Cap
5.23B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Lantheus Holdings | 1.50B |
Stevanato Group | 1.22B |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
Corcept Therapeutics | 628.56M |
ADMA Biologics | 382.81M |
Krystal Biotech | 241.52M |
RNA News
- 9 days ago - Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PRNewsWire
- 13 days ago - Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - PRNewsWire
- 21 days ago - Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PRNewsWire
- 4 weeks ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 2 months ago - Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases - Benzinga
- 2 months ago - Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month - PRNewsWire
- 3 months ago - Avidity Biosciences to Participate in Upcoming Investor Conferences - PRNewsWire